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M.S. Niederman et al.1782vs. 84.6%, P ¼ 0:019) and clarithromycin (90.1% vs. 64.2%, P ¼ 0:001) analysed
separately. Clinical success was 89.5% (128/143) for moxifloxacin vs. 85.2% (127/149)
for the macrolide group (P ¼ 0:278); similar results were found when moxifloxacin
was compared individually with each macrolide.
For patients with AECB due to H. influenzae, moxifloxacin provided superior
bacterial eradication rates than macrolide therapy.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Acute exacerbations of chronic bronchitis (AECB)
are a frequent complication among patients who
suffer from chronic bronchitis.1 They are associated
with significant patient and societal burden, largely
exemplified by the need for physician visits and/or
hospitalisation. For example, in the USA over 14
million cases of chronic bronchitis are reported
annually, with each patient experiencing an aver-
age of 1 acute exacerbation/year, and costs
exceeding US$1.6 billion/year (1995 data).2 In
addition, AECB is a common cause of mortality in
this patient population.3
Respiratory infections are assumed to be the
main risk factor for AECB. However, other non-
infectious aetiologies may also be involved, includ-
ing seasonal allergies, congestive heart failure, and
pulmonary embolism.4 Although there is continuing
debate regarding the role of bacterial infection, a
variety of micro-organisms have been shown to be
associated with AECB; in particular, Haemophilus
influenzae, Moraxella catarrhalis, and Streptococ-
cus pneumoniae.5 Several investigators have shown
that the presence of these bacteria may be related
to the severity of the patient’s underlying obstruc-
tive lung disease,6–8 and the acquisition of new
strains increases the risk of AECB,9 with patients
having no immunity against these infections.10
Accordingly, the administration of potent and
effective therapy, that will rapidly eradicate these
three commonly isolated bacteria, could be crucial
towards reversing the symptoms associated with
recurrent exacerbations and may prolong the time
to the next AECB episode.11,12
The choice of antimicrobial therapy remains
controversial for patients with AECB. The recently
published Canadian Thoracic Society and the
Canadian Infectious Disease Society guidelines
assign antimicrobial therapy by stratifying patients
into risk groups.13 Macrolides show generally good
clinical efficacy in mild or simple AECB and this is
reflected in the guideline recommendations.13
However, recent surveillance studies in the USA
and worldwide have found that 6–33% of H.
influenzae respiratory isolates produce b-lacta-mase,14–18 with multidrug resistance reported to
ampicillin, erythromycin, and/or trimethoprim-
sulphamethoxazole.15 The possible clinical impact
of in vitro macrolide resistance is difficult to
measure due to relatively high rates of spontaneous
resolution and the possibility of non-bacterial
aetiologies in AECB.19,20 However, by examining
bacteriological data from patients with proven
H. influenzae infection, differences among ther-
apeutic agents might be seen. The clinical impact
of such differences is uncertain, but could be
expressed as differences in the speed of clinical
success, or in the time to the next exacerbation.21
Moxifloxacin, one of the newer respiratory
fluoroquinolones, has excellent in vitro activity
against H. influenzae (minimum inhibitory concen-
tration (MIC)90 of 0.06mg/L) that is independent of
b-lactamase production or macrolide resistance
mechanisms. Several recent clinical trials have
established that moxifloxacin 400mg administered
once daily for 5 days was as effective as 7–10 days’
treatment with standard antibiotics for the treat-
ment of AECB.21–27
The objective of this pooled analysis from four
separate prospective, randomised double-blind
clinical trials in AECB was to evaluate the bacter-
iological and clinical efficacy of oral moxifloxacin
compared with two standard macrolide antimicro-
bials (i.e. azithromycin, clarithromycin) in the
treatment of adult patients with proven bacterial
episodes of AECB caused by H. influenzae alone or
concurrently with other commonly isolated respira-
tory pathogens.Patients and methods
Study design and location
This pooled analysis consisted of four clinical
trials that employed a similar study design. All
four studies were prospective, double-blind, multi-
centre, randomised trials comparing oral
moxifloxacin with oral macrolide therapy (azithro-
mycin or clarithromycin) in the treatment of AECB.
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days) was evaluated in each trial; one trial also
included a standard 10-day moxifloxacin treatment
regimen, though these data were not included in
the current analysis.26 Azithromycin (500mg load-
ing dose, followed by 250mgqd for 4 additional
days) was the comparator in two studies (one study
is unpublished)25; clarithromycin 500mg bid for 10
days was evaluated in the other two studies.26,27
Patients were enrolled at clinical sites distrib-
uted throughout North America (three trials)25,26
and Europe (one trial).27 All sites were clinic based
and managed by physicians who included primary
care physicians, pulmonologists, and infectious
disease specialists. Each trial was approved by
each investigator’s institutional review board, and
all patients gave written informed consent prior to
enrolment.Patients
Patients eligible for inclusion in the study were
adults (X18 years of age) with underlying chronic
bronchitis as defined by the daily production of
sputum on most days for at least 3 consecutive
months for more than 2 consecutive years and who
had an AECB clinically thought to be caused by a
bacterial pathogen. The acute nature of the
infection was documented by recent increases of
bronchopulmonary symptoms and laboratory evi-
dence of lower respiratory tract bacterial infec-
tion. Enrolment was restricted to patients who had
increased purulent/mucopurulent sputum and at
least one of the following: increased cough,
increased dyspnoea, increase of sputum volume,
or presence of fever (oral temperature 4100.4 1F
or 38 1C). Patients had to be suitable for oral
antimicrobial therapy on an outpatient basis.
Primary exclusion criteria included: severe re-
spiratory tract infections requiring parenteral anti-
microbial therapy or mechanical ventilatory
support; chest X-ray suggestive of a new pneumo-
nia; recent diagnosis or unresolved lung or chest
cavity malignancy; diagnosis of cystic fibrosis;
pregnancy or lactating; history of allergy or severe
adverse reactions to carboxyquinolone derivatives
or azalide/macrolide derivatives; previous history
of fluoroquinolone-related tendinopathy; neutro-
phil count o1000/mm3, CD4 count o200/mm3, or
other evidence of significant immunosuppression;
evidence of significant liver impairment (alanine
aminotranferase and aspartate aminotransferase or
total bilirubin, 43 times upper limit of normal);
renal insufficiency requiring dialysis; history of QTc
prolongation or taking drugs known to increase theQT interval; or the need for a concomitant
antibacterial agent with a spectrum of activity
similar to the study drugs. Prospective patients
were also excluded if they received previous
therapy with a systemic antibiotic for more than
24 h prior to enrolment.In vitro susceptibility testing
The susceptibility of H. influenzae to azithromycin,
clarithromycin, and moxifloxacin was determined
at each investigator’s microbiology laboratory using
standardised E-tests (AB Biodisk, Solna, Sweden).
In addition, all clinical isolates were sent to a
central laboratory (Bayer Corporation, Pharmaceu-
tical Division, West Haven, CT) for confirmation of
organism identity and for moxifloxacin susceptibil-
ity testing by the broth microdilution method. Disk
diffusion and broth microdilution susceptibility
testing were performed according to NCCLS guide-
lines.28–32 Haemophilus spp. were also tested for
b-lactamase production. The MIC of each
H. influenzae isolate was recorded using NCCLS/
CLSI interpretative criteria (antimicrobial sensitive
breakpoints) to clarithromycin (p8mg/L), azithro-
mycin (p4mg/L), and moxifloxacin (o1mg/L).
Clarithromycin non-susceptibility was 16mg/L and
resistance was X32mg/L.Bacteriological and clinical assessments and
definitions
For this pooled analysis, standardised bacteriologi-
cal evaluation (Gram stain and sputum culture)
and clinical assessment were performed pre-
therapy and at the test-of-cure visit (7–37 days
post-therapy).
Bacterial eradication was defined as confirmed
eradication or presumed eradication at test-of-cure
according to the following definitions: confirmed
eradication (original causative organisms absent on
repeat sputum culture); presumed eradication
(absence of appropriate culture material for
evaluation because the patient was a clinical
success and was unable to produce sputum);
persistence (original organisms still present on
sputum culture); presumed persistence (absence
of appropriate culture material for evaluation and
patient assessed as clinical failure); superinfection
(isolation of new pathogens/causative organisms
judged to be causing an infectious process in the
respiratory tract associated with clinical signs); and
indeterminate (bacteriological response of the
study drug not evaluable for any reason).
ARTICLE IN PRESS
M.S. Niederman et al.1784Clinical response was based on serial examina-
tions of the patient using the following parameters:
objective signs, including auscultatory findings
(rales, rhonchi, wheezing, breath sounds); prolon-
gation of expiratory phase; presence of fever
438 1C; presence of WBC 412,000 cells/mm3;
subjective symptoms of change in cough frequency
and severity; sputum characteristics (thickness and
volume); and dyspnoea, chest pain, or discomfort.
Clinical success at the test-of-cure visit (7–37 days
post-therapy) was defined as the proportion of
patients with clinical cure or improvement accord-
ing to the following definitions: clinical cure (return
to pre-exacerbation status, no additional antimi-
crobial therapy required); clinical improvement
(not complete return to pre-exacerbation status,
but sufficient improvement in clinical signs and
symptoms that no alternative antimicrobial therapy
was required); clinical failure (no change, worsen-
ing, insufficient improvement, or reappearance of
signs and symptoms of infection such that alter-
native antimicrobial therapy is required); and
indeterminate (clinical assessment not possible).Statistical analyses
For categorical demographic and baseline medical
characteristics, a w2 test was used to test for the
differences between the treatment groups. For
continuous variables, a one-way analysis of
variance was used, with a term included for
treatment.
Three populations were evaluated for clinical
and bacteriological responses: (1) any patient
considered microbiologically valid with a pre-
therapy H. influenzae pathogen, (2) the subset of
patients with an H. influenzae isolate plus the
presence of another co-pathogen, and (3) the
subset of patients with only H. influenzae identified
as a pre-therapy pathogen. For each evaluation of
clinical and bacteriological response, a retrospec-Table 1 Populations: four pooled studies of moxifloxacin
Population Moxifloxacin Macrolides
(combined)
Intent-to-treat, N 1280 1275
Microbiologically valid, n/
N (%)
460/1280
(35.9)
450/1275
(35.3)
H. influenzae total, n/N
(%)
143/460 (31.1) 149/450 (33.1
H. influenzae only n/N (%) 108/143 (75.5) 107/149 (71.8
H. influenzae plus other
pathogens, n/N (%)
35/143 (24.5) 42/149 (28.2)tive P-value was constructed for the difference
between the moxifloxacin and macrolide treatment
groups. These P-values should be considered
descriptive due to the retrospective nature of the
tests and the multiple comparisons involved.Results
A total of 2555 patients were included in the
intent-to-treat population (1280 moxifloxacin vs.
1275 macrolides) and comprised the pooled studies
database (Table 1). For the individual studies, the
number of patients in the intent-to-treat analysis
was: 374 moxifloxacin, 371 clarithromycin in the
European study,27 312 5-day moxifloxacin and 312
clarithromycin,26 and 283 moxifloxacin and 284
azithromycin25 in the two published US studies and
311 moxifloxacin and 308 azithromycin in the
unpublished study.
A pre-therapy bacterial pathogen was documen-
ted in 35.6% (910/2555) of the intent-to-treat
population (microbiologically valid population).
Within the microbiologically valid cohort, 292
(32.1%) H. influenzae isolates were confirmed
(143 moxifloxacin, 149 macrolides). H. influenzae
was the most commonly isolated organism in all
four studies. The majority of patients with
H. influenzae at baseline were not co-infected
with another respiratory tract pathogen (73.6%
[215/292]).
Of the 292 H. influenzae isolates, 17.8% (52/292)
were b-lactamase producers. Clarithromycin non-
susceptibility was noted for 27.6% (24/87) of strains
(data available from one study only), and 19.7%
(14/71) were non-susceptible to azithromycin (data
available from one study only). Pre- and post-
therapy MICs for the macrolide-treated patients
from these two studies are shown in Table 2. The
MIC range for clarithromycin was 0.032–256mg/L
(MIC90 16mg/L) and for azithromycin wasvs. macrolides.
Azithromycin Clarithromycin Total
592 683 2555
207/592 (35.0) 243/683 (35.6) 910/2555 (35.6)
) 65/207 (31.4) 84/243 (34.6) 292/910 (32.1)
) 57/65 (87.7) 50/84 (59.5) 215/292 (73.6)
8/65 (12.3) 34/84 (40.5) 77/292 (26.4)
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Table 2 MICs (in the two studies where data are
available) pre- and post-therapy for macrolide-
treated patients with persistent H. influenzae.
Patient # MIC (mg/L)
Pre-therapy Post-therapy
Azithromycin study
A 2 4
B 4 8
C 3 6
D 4 4
Clarithromycin study
a 8 8
b 8 8
c 16 16
d 16 16
e 4 16
f 8 32
g 0.25 16
h 8 8
i 16 16
j 16 32
k 8 32
l 16 16
m 16 8
n 1 1
o 8 0.5
p 8 32
q 4 16
r 8 8
s 4 8
t 8 32
These isolates were not finger printed. It is possible
that the post-therapy isolate could represent a new
infection.
Moxifloxacin against H. influenzae in AECB 17850.094–12mg/L (MIC90 8mg/L). All respiratory
H. influenzae isolates recovered from these clinical
studies were fully susceptible to moxifloxacin and
the range of moxifloxacin MICs was 0.03–1.0mg/L
(MIC90 0.125mg/L).Demographics and baseline medical
characteristics
For the H. influenzae cohort (regardless of co-
pathogen presence), the moxifloxacin and macro-
lide treatment groups were well balanced for
demographics and current infection characteristics
(Table 3). Approximately 62% of patients in both
treatment groups had p2 exacerbations/year, with
15.4% in the moxifloxacin group and 10.7% in the
macrolide group reporting 44 exacerbations/year.
The vast majority of patients (87% per treatmentgroup) reported a smoking history and at least 56%
were current smokers. Anthonisen exacerbation
class data were collected in the two published US
studies,25,26 with 79.2% (57/72) patients in the
moxifloxacin group Type I and the remainder Type II
and in the macrolide group 77.9% (60/77) of
patients were Type I, 24.7% Type II and one patient
Type III.
A very small proportion of patients (o1.5%)
received antimicrobial therapy within a week prior
to receiving a study antimicrobial. It is also
noteworthy that the H. influenzae cohort re-
sembled the entire microbiologically valid popula-
tion in terms of demographic and baseline medical
characteristics (data not shown). In addition,
similar baseline demographics and infection char-
acteristics were observed in the H. influenzae
alone and H. influenzae plus co-pathogen patient
cohorts (data not shown).Bacteriological outcomes
Bacterial eradication rates at the test-of-cure visit
were 93.0% (133/143) for moxifloxacin-treated
patients with H. influenzae infection compared
with 73.2% (109/149) in the macrolide group
(P ¼ 0:001) (Fig. 1). For the moxifloxacin group,
of the 133 patients with bacterial eradication, 44
were confirmed and 89 presumed eradication. For
the macrolide group, of the 109 patients with
bacterial eradication, 15 were confirmed and 94
presumed eradication. Among bacteriological fail-
ures, in the moxifloxacin group there were seven
presumed persistence and three confirmed persis-
tence, and in the comparator group there were
seven presumed persistence and 33 confirmed
persistence. Similar results were obtained when
eradication rates for moxifloxacin were compared
with those obtained independently with azithro-
mycin (96.8% [60/62] vs. 84.6% [55/65], respec-
tively, P ¼ 0:019) and clarithromycin (90.1% [73/
81] vs. 64.3% [54/84], respectively, P ¼ 0:001).
Bacterial eradication rates continued to signifi-
cantly favour moxifloxacin when patients were
stratified by infection due to H. influenzae alone
or with a co-pathogen (Fig. 1). The bacteriologic
eradication rate was lower in patients with macro-
lide-resistant organisms, who were treated with a
macrolide (13/20) than in patients with a macro-
lide-resistant organism who was treated with
moxifloxacin (16/18).
In the one clarithromycin and one azithromycin
study where non-susceptibility data were available,
the eradication rate with moxifloxacin in patients
with macrolide-resistant or non-susceptible
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Figure 1 Bacterial eradication rates for H. influenzae by patient at test-of-cure visit (7–37 days post-therapy).
Table 3 Demographics and baseline medical characteristics for patients with positive H. influenzae culture at
baseline.
Characteristics Moxifloxacin
(N ¼ 143)
Macrolides
(combined)
(N ¼ 149)
Azithromycin
(N ¼ 65)
Clarithromycin
(N ¼ 84)
Mean age, year7SD (range) 56714 55715 53714 57715
(21–89) (19–90) (28–82) (19–90)
Sex, n (%) male 85 (59.4) 96 (64.4) 44 (67.7) 52 (61.9)
Race, n (%) Caucasian 99 (69.2) 96 (64.4) 35 (53.8) 61 (72.6)
Mean number of exacerbations
in prior year7SD
2.471.7 2.271.5 1.871.3 2.471.5
p2 exacerbations in prior
year, n (%)
90 (62.9) 92 (61.7) 48 (73.8) 44 (52.3)
3–4 exacerbations in prior
year, n (%)
31 (21.7) 41 (27.5) 12 (18.5) 29 (34.5)
44 exacerbations in prior
year, n (%)
22 (15.4) 16 (10.7) 5 (7.7) 11 (13.1)
History of cigarette smoking,
past or present, n (%)
125 (87.4) 130 (87.2) 61 (93.8) 69 (82.1)
Current cigarette smoker, n
(%)
86 (60.1) 84 (56.4) 43 (66.2) 41 (48.8)
Mean length of smoking history
(year)7SD
33715 32715 30713 33716
Mean pack years smoked7SD 45.5728 42.0729 43.5730 41.5728
Recent antimicrobial therapy
(o1 week), n (%)
2 (1.4) 2 (1.3) 0 2 (2.4)
Characteristics for the moxifloxacin and macrolide groups were similar (P40:05 for all comparisons).
M.S. Niederman et al.1786H. influenzae was 88.9% (16/18) and in macrolide-
susceptible patients it was 95.1% (58/61). For the
macrolides, the eradication rate for macrolide-resistant or non-susceptible H. influenzae was
65.0% (13/20) and was 67.8% (40/59) for macro-
lide-susceptible H. influenzae.
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characteristics (age, number of exacerbations in
past year, smoking status, and recent antimicrobial
therapy) for the entire H. influenzae group re-
vealed that age did not influence bacteriological
outcome for either the moxifloxacin or macrolide
treatment groups (data not shown). However,
macrolide-treated patients with 44 exacerbations
within the prior year tended to have a lower rate of
bacterial eradication compared with those who
reported p4 exacerbations (62.5% [10/16] vs.
74.4% [99/133], respectively, P ¼ 0:31). For moxi-
floxacin, the bacterial eradication rate was similar
between patients with 44 vs. p4 exacerbations/
year; 95.5% [21/22] and 92.6% [112/121], respec-
tively (P ¼ 0:63). Although the numbers of patients
were small, in patients with 44 exacerbations in
the last year, the bacterial eradication rate was
significantly higher with moxifloxacin (95.5% [21/
22]) vs. macrolides (62.5% [10/16], P ¼ 0:01).
Clinical outcomes
Clinical success rates at the test-of-cure visit are
shown in Fig. 2. Rates of clinical success by
treatment did not vary when patients were
stratified with infection due to H. influenzae alone
or with a co-pathogen (Fig. 2). Clinical success
rates for the entire H. influenzae cohort (with or
without a co-pathogen) were similar for the
moxifloxacin vs. macrolide treatment groups:
89.5% vs. 85.2%, respectively (P ¼ 0:278). There89.8
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Figure 2 Clinical success rates for H. influenzae by pawas a trend towards higher clinical success with
moxifloxacin vs. azithromycin (90.3% [56/62] vs.
81.5% [53/65], respectively, P ¼ 0:155) and no
significant difference in clinical response vs.
clarithromycin (88.9% [72/81] vs. 88.1% [74/84],
respectively, P ¼ 0:873).
Clinical success rates with moxifloxacin for the
patients in the two studies where macrolide
susceptibility and resistance were determined were
94.4% (17/18) for macrolide-resistant plus non-
susceptible H. influenzae and 90.2% (55/61) for
macrolide-susceptible H. influenzae. Treatment
with macrolides in the macrolide-resistant or non-
susceptible H. influenzae population resulted in a
clinical success rate of 95.0% (19/20) and in the
macrolide-susceptible population this was 83.1%
(49/59).
An analysis of various demographic and medical
characteristics found no influence of these on
clinical outcome at the test-of-cure visit (7–37
days post-therapy). Moxifloxacin-treated patients
had similar high clinical response rates against H.
influenzae regardless of patient age (X89.1%),
number of exacerbations in last year (X87.8%), or
history of cigarette smoking (X87.2%). There was
no influence of these characteristics on clinical
success within the macrolide treatment group,
though there was a trend towards lower rates of
clinical cure in clarithromycin-treated patients who
had44 exacerbations in the past 12 months (72.7%
[8/11]) vs. those withp4 exacerbations in the past
year (90.4% [66/73], P ¼ 0:09). For moxifloxacin,88.6
(31/35)08) 83.3
(35/42)
86.0
(92/107)
enzae only H. influenzae plus
co-pathogen
P = 0.513 = 0.389
tient at test-of-cure visit (7–37 days post-therapy).
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44 exacerbations in the past year vs. 88.4% [107/
121] for patients withp4 exacerbations (P ¼ 0:32).
There was no difference in clinical cure among
patients with 44 exacerbations for the moxiflox-
acin group vs. the combined macrolide group
(P ¼ 0:097).
Overall, clinical outcomes for the H. influenzae
cohort paralleled observations for the entire
microbiologically valid group (data not shown).
Also, none of the demographic/medical character-
istics appeared to influence clinical outcome for
either the moxifloxacin or macrolide treatment
groups within the H. influenzae only or the
H. influenzae plus co-pathogen cohorts (data not
shown).Correlation of clinical and bacteriological
responses
A retrospective exploratory analysis was per-
formed, irrespective of the antibiotic regimen
received, to determine if bacteriological and
clinical responses were correlated. It must be
noted that the majority of patients were unable
to produce sputum at the test-of-cure visit. As
such, for these patients, the bacteriological
responses were based on the clinical responses
(i.e. presumed eradication or presumed persis-
tence). In patients with valid pre- and post-therapy
H. influenzae sputum culture, the clinical success
rate was 78.0% (46/59) for patients with confirmed
bacterial eradication, and 69.4% (25/36) for those
with confirmed persistence (P ¼ 0:354).Time to resolution of clinical signs and
symptoms
Data on time to symptoms resolution were
available for two of the four studies, both
conducted in the USA (one unpublished).26 The
time to resolution of individual symptoms did not
appear to vary significantly between the moxiflox-
acin and macrolide treatment groups. In terms of
the resolution of all the signs and symptoms of
AECB, at baseline, 95.3% of moxifloxacin-treated
patients had at least one sign/symptom compared
with 74.7% during therapy (20.6% decrease from
baseline). For the macrolide treatment group,
97.1% patients had at least one sign/symptom at
baseline vs. 83.0% during therapy (14.1% decrease
from baseline). Thus, at the during therapy visit,
25.3% of all moxifloxacin-treated patients returned
to their pre-exacerbation clinical status comparedwith 17.0% of patients in the macrolide group
(P40:29).Discussion
The management of respiratory tract infections,
including AECB, has become an increasing challenge
due to the rising prevalence of antimicrobial
resistance. The use of optimal antimicrobial ther-
apy that achieves bacterial eradication is thought to
be important for maximising clinical outcomes and
reducing the potential for the development and
spread of resistance.33–35 In this study, the bacterial
eradication rate of H. influenzae with macrolides
was 73.2% vs. 93.0% for moxifloxacin (P ¼ 0:001).
Furthermore, analysis of the individual comparators
showed that both clarithromycin and azithromycin
had significantly lower rates of H. influenzae
eradication compared with moxifloxacin.
Although there was a significant difference in
bacterial eradication between moxifloxacin and
macrolides in this study, there was no difference
in clinical outcomes. AECB can be caused by a
variety of non-bacterial aetiologies, and in order to
more accurately assess relative antibiotic effec-
tiveness, only those patients with a proven pre-
therapy H. influenzae infection were included in
the current analysis. However, a recent study found
that approximately 17% of patients with stable
chronic obstructive pulmonary disease have
H. influenzae cultured from bronchial brush sam-
ples vs. 30% for patients with AECB.36 In patients
with stable disease, the bacterial load was sig-
nificantly lower than during an exacerbation.36 In
the current study, bacterial load was not deter-
mined, so it is possible that, although patients were
infected with H. influenzae, a proportion of them
would have an alternative cause of their exacer-
bation. If the bacterial infection is not the major
driver of the clinical manifestations of AECB in all
cases then it could be one explanation for the
dissociation between clinical and bacteriological
outcome would be expected.
The lower bacteriologic eradication rate of
H. influenzae in the respiratory tract of AECB
patients treated with macrolides is an important
finding with potentially significant clinical conse-
quences. There is evidence to suggest that failure
to completely eradicate H. influenzae may lead to
late relapse or shortened time between exacerba-
tions.11,12,21 In the current study, analysis was
limited to data collected through the test-of-cure
visit (7–37 days post-therapy) and the time to next
exacerbation is not known. However, in studies
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next exacerbation, treatment of AECB with the
fluoroquinolones ciprofloxacin,11 gemifloxacin,12 or
moxifloxacin21 demonstrated statistically superior
exacerbation-free intervals against standard
therapy, including antibiotics such as macrolides
and b-lactamase.
In a multicentre, double-blind, randomised
trial, a relatively high rate of persistence with
H. influenzae was observed among clarithromycin-
treated patients, in contrast to complete eradica-
tion following ciprofloxacin treatment.11 While
clinical cure rates at the end of therapy were
similar between the ciprofloxacin (90%) and clari-
thromycin (82%) treatment groups, there was a
significant difference in bacterial eradication (91%
vs. 77%, respectively, P ¼ 0:01). Patients who
received ciprofloxacin had a three-fold longer
infection-free interval (i.e. time from one exacer-
bation to the next; 142 days) compared with
clarithromycin (51 days, P ¼ 0:15).11 In the gemi-
floxacin study, 71.0% of patients treated with the
fluoroquinolone had at least 26 weeks before the
next AECB episode vs. 58.5% with clarithromycin
(P ¼ 0:02).12 Again, this longer infection-free inter-
val was associated with a significantly higher
bacterial eradication rate with gemifloxacin at
long-term follow-up (days 25–38) compared with
clarithromycin (81.8% vs. 62.0%, respectively, 95%
CI, 2.2–37.5).12 In the moxifloxacin study, the
median time until the next exacerbation was 131
days vs. 103.5 days with standard therapy
(P ¼ 0:03).21 In addition, moxifloxacin-treated pa-
tients had a significantly higher bacteriological
success rate compared with those receiving stan-
dard antibiotic regimens (91.5% vs. 81.0%, respec-
tively, 95% CI, 0.4–22.1).21 These studies suggest
that bacterial eradication may be an important
factor in extending the period between AECB
episodes.
A limitation of this study was that the endpoint of
bacterial eradication was a composite of micro-
biologically confirmed eradication and presumed
eradication, based on clinical cure. Overall, of the
242 patients with bacterial eradication, 59 (24.4%)
were confirmed eradication and 183 (75.6%) were
presumed eradication. This is a limitation in most
studies of bacteriological outcomes AECB because
as patients get better it becomes more difficult for
them to produce evaluable sputum samples. How-
ever, all of the studies in this analysis were double
blind and this would have removed most potential
for bias through the linking of clinical and bacter-
iological endpoints. In addition, the majority of
patients that failed therapy had confirmed bacter-
ial persistence (36/50 [72.0%]). Although broncho-scopic sampling pre- and post-therapy might have
dealt with this question, this is not a practical
solution or one that could be easily performed on a
large number of patients representative of a full
spectrum of AECB. One other limitation to our data
set is the fact that 35 patients were younger than
40, and 30 were never smokers; three patients
were both o40 and never smokers, these patients
are not representative of the usual type of patient
who meets the clinical definition of AECB. A further
limitation, common to most AECB studies, is that
bacterial strains were not serotyped so it is
unknown whether the baseline strain is the same
as strains detected later in the study.
The current data demonstrate that moxifloxacin
is an effective therapy for patients with AECB who
had infections or co-infections with H. influenzae,
with higher bacterial eradication rates as compared
with macrolides: azithromycin and clarithromycin.
Newer-generation fluoroquinolones, such as moxi-
floxacin, should be used appropriately—when
commonly encountered organisms are known or
suspected to be resistant to traditional therapies.
The clinical implications of these findings deserve
further investigation.Acknowledgement
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